Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BioXcel Therapeutics, Inc. (BTAIQ) vs Neptune Wellness Solutions Inc. (NEPTF)

BioXcel Therapeutics, Inc. and Neptune Wellness Solutions Inc. are both Drug Manufacturers Specialty & Generic companies. BioXcel Therapeutics, Inc. is the larger, with a market value of $2.3M against $1.6M — 1.4× the size. BioXcel Therapeutics, Inc. grew revenue faster over the last twelve months: −14.5% against −24.8%. Neptune Wellness Solutions Inc. has the higher net margin (−135.2% vs −9,549.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 14 metrics below, Neptune Wellness Solutions Inc. leads on 9 and BioXcel Therapeutics, Inc. on 5.

Valuation

Metric BTAIQ NEPTF Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 1.63 n/m 2.25
P/B n/m n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 228.73 1.06 2.56
Earnings yield (9,475.00%) 0.00% (2.99%)
Free cash flow yield (4,201.65%) 0.00% 0.00%

Profitability

Metric BTAIQ NEPTF Drug Manufacturers Specialty & Generic median
Gross margin 53.10% (1.94%) 53.94%
Operating margin (6,054.72%) (190.39%) 0.00%
Net margin (9,549.87%) (135.24%) 0.00%
Free cash flow margin (6,860.38%) (40.57%) 0.00%
Return on equity 63.52% 291.47% (0.40%)
Return on assets (259.62%) (121.62%) (3.32%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BTAIQ NEPTF Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (14.52%) (24.78%) 10.01%
EPS growth (last fiscal year) 75.63% 67.05% —
Revenue growth, 5-year CAGR — 19.52% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BTAIQ NEPTF Drug Manufacturers Specialty & Generic median
Debt to equity (0.90) (0.50) 0.05
Current ratio 0.21 0.23 2.31
Net debt to EBITDA (1.61) (0.21) 0.85

Dividend

Metric BTAIQ NEPTF Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric BTAIQ NEPTF Drug Manufacturers Specialty & Generic median
Market cap 2.31m 1.60m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack